Precision medicine in Hepatitis B: the diagnostic power of biomarkers

4月 7, 2025 Bullet 第
Seng Gee LimSeng Gee Lim
会議 感染症 肝疾患と HCC Singapore
共有する：
リンクをコピーする
hepatitis b treatment​

Prof Seng Gee Lim, Director of Hepatology, Department of Gastroenterology and Hepatology at Singapore’s National University Health System, promotes the use of biomarkers in diagnostics to manage and allow tailored, personalised treatment for patients with hepatitis B, contributing to the overall improvement of patient outcome.

共有する：
リンクをコピーする

同じトピックの記事

Select a related post from the options below.

Taiwan’s Hepatitis C elimination journey: lessons in diagnostics-driven prevention

Addressing the underdiagnosis of Hepatitis E in Vietnam with Dr Nguyen Nguyen Huyen

おすすめのトピック

配列決定レッド2020希少疾患
次のおすすめ記事
管理
• 記事
Creating a healthier Singapore with digital solutions: Q&A with Glenn Neo
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
管理
• 記事
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
運用
• 記事
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
運用
• 記事
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top